Cigna earnings beat by $0.04, revenue topped estimates
In recent trading activity involving Alumis Inc. (NASDAQ:ALMS), Foresite Labs, LLC, a significant stakeholder, reported acquiring additional shares of the company. According to a recent SEC filing, Foresite Labs purchased a total of 45,000 shares over two transactions. The acquisitions took place on May 2 and May 6, 2025, at prices ranging from $4.34 to $4.62 per share. This brings the total value of the transactions to approximately $202,300. The purchases come as the stock trades near $4.35, having declined over 62% in the past six months.
The shares were acquired indirectly, with Foresite Labs, LLC and its affiliate, Foresite Labs Affiliates 2021, LLC, holding a 10% ownership stake in Alumis Inc. These transactions have increased Foresite Labs’ total holdings in the company, reflecting its continued interest in Alumis Inc.’s prospects. Despite the recent stock performance, analysts maintain highly bullish targets, and the company boasts a strong liquidity position with a current ratio of 6.01. InvestingPro analysis reveals 8 additional key insights about Alumis’s financial health and growth prospects.
In other recent news, Alumis Inc. has announced a revised merger agreement with Acelyrin, adjusting the exchange ratio to increase Acelyrin stockholders’ ownership to approximately 48%, while Alumis stockholders will retain about 52% of the combined entity. The merger is expected to close in the second quarter of 2025, pending stockholder approval. Alongside this, H.C. Wainwright has adjusted its price target for Alumis to $14 from $15, while maintaining a Buy rating, following the merger announcement. Additionally, Alumis has entered into a strategic collaboration with Kaken Pharmaceutical (TADAWUL:2070) for the development and commercialization of ESK-001 in Japan, with potential earnings up to $180 million from upfront, milestone, and royalty payments. This agreement allows Kaken to manage clinical development and regulatory processes in Japan, while Alumis retains rights elsewhere. The partnership is aimed at leveraging Kaken’s expertise in dermatology to advance ESK-001, currently in Phase 3 trials for moderate-to-severe plaque psoriasis. The collaboration underscores a significant step in Alumis’ strategy to enhance its global presence in dermatology treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.